| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0264-410X(02)00456-5 |
| P698 | PubMed publication ID | 12450695 |
| P50 | author | Jesús Prieto | Q28324697 |
| Gláucia Paranhos-Baccalà | Q70967654 | ||
| Ascensión López-Díaz de Cerio | Q88051678 | ||
| Noelia Casares | Q93038508 | ||
| Francisco Borrás-Cuesta | Q117233005 | ||
| Laura Arribillaga | Q117283728 | ||
| Marta Gorraiz | Q117283732 | ||
| Pablo Sarobe | Q39790261 | ||
| Oscar Bruna-Romero | Q40687756 | ||
| Juan José Lasarte | Q40687778 | ||
| P2093 | author name string | Juan Ruiz | |
| Africa Vales | |||
| P2860 | cites work | Human Immunodeficiency Virus Type 1-Hepatitis C Virus Coinfection: Intraindividual Comparison of Cellular Immune Responses against Two Persistent Viruses | Q27472844 |
| Quantitative analysis of hepatitis C virus-specific CD8(+) T cells in peripheral blood and liver using peptide-MHC tetramers | Q27485114 | ||
| Determinants of viral clearance and persistence during acute hepatitis C virus infection | Q28131757 | ||
| Immune response in mice that lack the interferon-gamma receptor | Q62022366 | ||
| A simple technique for the rescue of early region I mutations into infectious human adenovirus type 5 | Q64379529 | ||
| Induction of cytotoxic T lymphocytes in mice against the principal neutralizing domain of HIV-1 by immunization with an engineered T-cytotoxic-T-helper synthetic peptide construct | Q68054239 | ||
| The viral clearance in interferon-treated chronic hepatitis C is associated with increased cytotoxic T cell frequencies | Q72995509 | ||
| A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells | Q29615897 | ||
| Analysis of a successful immune response against hepatitis C virus | Q29619507 | ||
| Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection | Q29620141 | ||
| Cellular immune responses persist and humoral responses decrease two decades after recovery from a single-source outbreak of hepatitis C | Q29620614 | ||
| Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response | Q29620891 | ||
| Protective immunity in macaques vaccinated with a modified vaccinia virus Ankara-based measles virus vaccine in the presence of passively acquired antibodies. | Q33803714 | ||
| Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif | Q34199652 | ||
| Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus | Q34301871 | ||
| Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector | Q35068584 | ||
| Endogenous peptides of a soluble major histocompatibility complex class I molecule, H-2Lds: sequence motif, quantitative binding, and molecular modeling of the complex | Q36232156 | ||
| Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease | Q36361227 | ||
| H-2Dd exploits a four residue peptide binding motif | Q36362613 | ||
| Molecularly engineered vaccine which expresses an immunodominant T-cell epitope induces cytotoxic T lymphocytes that confer protection from lethal virus infection. | Q36831093 | ||
| The importance of local mucosal HIV-specific CD8(+) cytotoxic T lymphocytes for resistance to mucosal viral transmission in mice and enhancement of resistance by local administration of IL-12. | Q37388157 | ||
| Viral mutations, TCR antagonism and escape from the immune response. | Q40380488 | ||
| Effect of interferon-alpha therapy on epitope-specific cytotoxic T lymphocyte responses in hepatitis C virus-infected individuals | Q40761226 | ||
| Peptides naturally presented by MHC class I molecules | Q40898177 | ||
| Recognition of a novel naturally processed, A2 restricted, HCV-NS4 epitope triggers IFN-gamma release in absence of detectable cytopathicity | Q40992266 | ||
| High-level expression of the measles virus nucleocapsid protein by using a replication-deficient adenovirus vector: induction of an MHC-1-restricted CTL response and protection in a murine model | Q41326234 | ||
| Insights on the amino acid side-chain interactions of a synthetic T-cell determinant | Q41677424 | ||
| Human cytomegalovirus-specific cytotoxic T cells. Relative frequency of stage-specific CTL recognizing the 72-kD immediate early protein and glycoprotein B expressed by recombinant vaccinia viruses | Q42120952 | ||
| Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment | Q42979066 | ||
| Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus | Q42981208 | ||
| Long-term follow-up of patients with chronic hepatitis C treated with α-interferon | Q42981340 | ||
| Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C. | Q42988942 | ||
| Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. | Q42989853 | ||
| Role of the specific T-cell response for clearance and control of hepatitis C virus | Q42998171 | ||
| Association of hepatitis C virus-specific CD8+ T cells with viral clearance in acute hepatitis C. | Q42998720 | ||
| Oral immunization with HCV-NS3-transformed Salmonella: induction of HCV-specific CTL in a transgenic mouse model | Q43035107 | ||
| Randomised trial of lymphoblastoid alpha-interferon in chronic hepatitis C. Effects on inflammation, fibrogenesis and viremia | Q43048085 | ||
| Protection elicited by a replication-defective adenovirus vector expressing the tick-borne encephalitis virus non-structural glycoprotein NS1. | Q43049588 | ||
| T-lymphocyte response to hepatitis C virus in different clinical courses of infection | Q44044022 | ||
| Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity | Q45734062 | ||
| Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I | Q45752944 | ||
| Mucosal immunity and protection after intranasal immunization with recombinant adenovirus expressing herpes simplex virus glycoprotein B. | Q45776121 | ||
| Overexpression of HIV-1 proteins in Escherichia coli by a modified expression vector and their one-step purification. | Q54650487 | ||
| T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections | Q58802894 | ||
| P433 | issue | 3-4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Adenoviridae | Q193447 |
| Hepatitis C virus | Q708693 | ||
| Vaccinia virus | Q1986297 | ||
| vector-borne disease | Q2083837 | ||
| P304 | page(s) | 202-210 | |
| P577 | publication date | 2002-12-01 | |
| P1433 | published in | Vaccine | Q7907941 |
| P1476 | title | Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus | |
| P478 | volume | 21 |
| Q27472927 | A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques |
| Q37300367 | Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection |
| Q37689799 | Adenovirus-vectored vaccines |
| Q34353523 | Adenoviruses as vaccine vectors |
| Q43040768 | An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses |
| Q60232497 | Current status of a hepatitis C vaccine: Encouraging results but significant challenges ahead |
| Q36376020 | DNA Vaccination Protects Mice against Challenge withListeria monocytogenesExpressing the Hepatitis C Virus NS3 Protein |
| Q36198667 | Development of prophylactic and therapeutic vaccines against hepatitis C virus |
| Q35576891 | Effect of route of delivery on heterologous protection against HCV induced by an adenovirus vector carrying HCV structural genes |
| Q43035679 | Enhanced T cell responses against hepatitis C virus by ex vivo targeting of adenoviral particles to dendritic cells |
| Q42985317 | Enhanced hepatitis C virus NS3 specific Th1 immune responses induced by co-delivery of protein antigen and CpG with cationic liposomes |
| Q42992104 | Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus |
| Q35842662 | Gene therapy of liver diseases |
| Q31112300 | Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen |
| Q27485419 | Hepatitis C Virus Structural Proteins Impair Dendritic Cell Maturation and Inhibit In Vivo Induction of Cellular Immune Responses |
| Q27486582 | Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and [...] |
| Q45404856 | Induction of potent cellular immune response in mice by hepatitis C virus NS3 protein with double-stranded RNA. |
| Q45351044 | Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. |
| Q43000237 | Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse. |
| Q41087956 | Priming with two DNA vaccines expressing hepatitis C virus NS3 protein targeting dendritic cells elicits superior heterologous protective potential in mice |
| Q54563184 | Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2. |
| Q36550201 | Recent Advances in Development of DNA Vaccines Against Hepatitis C virus. |
| Q42231335 | Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum |
| Q39770989 | Recombinant influenza viruses as delivery vectors for hepatis B virus epitopes |
| Q37093594 | Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus |
| Q42248450 | Selection of conserved epitopes from hepatitis C virus for pan-populational stimulation of T-cell responses. |
| Q38758212 | T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates. |
| Q28741996 | The human metapneumovirus matrix protein stimulates the inflammatory immune response in vitro |
| Q40106073 | Unsolved Puzzles Surrounding HCV Immunity: Heterologous Immunity Adds Another Dimension |
| Q40070362 | Vaccination against hepatitis C virus with dendritic cells transduced with an adenovirus encoding NS3 protein. |
Search more.